Craft

Merck Summary

Overview

Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals. The company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

TypePublic
Founded1891
HQKenilworth, NJ, USMap
Websitemerck.com
Employee Ratings
4.2
More
Overall CultureBMore

Locations

Merck is headquartered in
Kenilworth, United States

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Dec 2019)71,000(+3%)
Job Openings2,820
Website Visits (Feb 2021)1 m(+37%)
Revenue (FY, 2020)$48 B(+2%)
Share Price (Apr 2021)$77.4
Cybersecurity ratingAMore

Key People/Management at Merck

Merck Office Locations

Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and in 253 other locations

Merck Financials and Metrics

Merck Revenue

Merck's revenue was reported to be $47.99 b in FY, 2020

USD

Revenue (FY, 2020)$47.99 b
Gross profit (FY, 2020)$32.51 b
Gross profit margin (FY, 2020), %67.7%
Net income (FY, 2020)$7.08 b
Market capitalization (27-Apr-2021)$195.82 b
Closing stock price(27-Apr-2021)$77.36
Cash (31-Dec-2020)$8.06 b
EV $219.55 b

Merck's current market capitalization is $195.8 b.

USDFY, 2017FY, 2018FY, 2019FY, 2020
Revenue40.1 b42.3 b46.8 b48 b
Revenue growth, %1%5%11%
Cost of goods sold12.8 b13.5 b14.1 b15.5 b
Gross profit27.3 b28.8 b32.7 b32.5 b
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Revenue10 b10.5 b10.8 b10.8 b11.8 b12.4 b12.1 b10.9 b12.6 b
Cost of goods sold3.2 b3.4 b3.6 b3.1 b3.4 b4 b3.3 b3.2 b3.5 b
Gross profit6.9 b7 b7.2 b7.8 b8.4 b8.4 b8.7 b7.7 b9.1 b
Gross profit Margin, %68%67%66%72%71%68%73%71%72%
show all

USDFY, 2017FY, 2018FY, 2019FY, 2020
Cash6.1 b8 b9.7 b8.1 b
Accounts Receivable6.9 b7.1 b6.8 b7.9 b
Inventories5.1 b5.4 b6 b6.3 b
Current Assets24.8 b25.9 b27.5 b27.8 b
show all

USDFY, 2017FY, 2018FY, 2019FY, 2020
Net Income2.4 b6.2 b9.8 b7.1 b
Depreciation and Amortization4.6 b4.5 b3.7 b1.9 b
Accounts Receivable297 m(418 m)294 m(1 b)
Inventories(145 m)(911 m)(508 m)(855 m)
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Net Income741 m2.5 b4.4 b2.9 b5.5 b7.4 b3.2 b6.2 b9.2 b
Depreciation and Amortization1.1 b2.4 b3.4 b898 m1.9 b2.7 b821 m1.9 b2.7 b
Cash From Operating Activities1.2 b4.5 b7.3 b1.3 b4.4 b8.6 b707 m4.1 b6.2 b
Capital Expenditures(450 m)(1 b)(1.7 b)(595 m)(1.4 b)(2.3 b)(986 m)(1.7 b)(3.2 b)
show all

USD
FY, 2020
EV/CFO22.5 x
Financial Leverage3.6 x
  • Merck Market Cap History

  • Merck Stock Price

Revenue Breakdown

Merck revenue breakdown by business segment: 9.4% from Animal Health, 89.1% from Pharmaceutical and 1.5% from Other

Merck revenue breakdown by geographic segment: 6.3% from Asia Pacific (other than Japan and China), 6.8% from China, 5.3% from Latin America, 27.1% from Europe, Middle East and Africa, 43.4% from United States, 7.6% from Japan and 3.4% from Other

Merck Operating Metrics

Merck's Phase III Trials Products was reported to be 25 in Nov, 2020.

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018FY, 2018FY, 2019Apr, 2020Aug, 2020Nov, 2020
Drugs Approved by FDA1
Phase III Trials Products241820201724242425
Projects in R&D Pipeline4110
Products309893102

Merck Acquisitions / Subsidiaries

Company NameDateDeal Size
OncoImmuneNovember 23, 2020$425 m
VelosBioNovember 06, 2020$2.75 b
Themis BioscienceMay 26, 2020
ArQuleDecember 09, 2019$2.7 b
Calporta Therapeutics, Inc.November 13, 2019$576 m
Tilos TherapeuticsJune 10, 2019$773 m
Peloton TherapeuticsMay 21, 2019$2.25 b
ConnectMedApril 05, 2019
Immune DesignFebruary 21, 2019$300 m
Antelliq GroupDecember 14, 2018$2.4 b

Human Capital Metrics

Source: msd20-assets.s3.amazonaws.com

Merck Hiring Categories

Merck Median Salaries

Source: 8 public H-1B filings from Merck

Merck Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Merck Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Merck Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

Merck Online and Social Media Presence

Twitter followers

208.04 k Twitter followers

6 Months

Merck has 208.04 k Twitter Followers. The number of followers has increased 0.98% month over month and increased 2.03% quarter over quarter.

Merck's Trends

Search term - Merck

Twitter Engagement Stats for @merck

  • 8.76 k

    Tweets

  • 1 k

    Following

  • 208.04 k

    Followers

  • 33

    Tweets last 30 days

  • 24.2

    Avg. likes per Tweet

  • 100%

    Tweets with engagement

Merck Technology StackBuildWith Logo

  • ads

    2 products used

    • DoubleClick.Net
    • ExactTarget
  • analytics

    7 products used

    • DoubleClick Floodlight
    • Facebook Domain Insights
    • Global Site Tag
      • Google Analytics
      • Google Universal Analytics
      • Tealium UTAG
      • WebTrends
  • cdn

    10 products used

    • AJAX Libraries API
    • Akamai
    • Akamai Global Host
      • CDN JS
      • Cloudflare
      • Cloudflare JS
      • Content Delivery Network
      • jsDelivr
      • OSS CDN
      • WordPress Grid
  • cdns

    1 product used

    • Akamai Edge
Learn more on BuiltWith

Merck Company CultureCultureAndCompensation Logo

  • Overall Culture

    B

    72/100

  • CEO Rating

    A-

    75/100

  • Compensation

    A-

    76/100

  • Diversity

    A-

    76/100

Learn more on Comparably

Merck News and Updates

Apr 27, 2021
How Merck works with Seeqc to cut through quantum computing hype
_3xOCqPharmaceutical giant Merck is partnering with startup Seeqc to monitor quantum developments while keeping an open mind.
Apr 27, 2021
Merck in licensing deals with 5 Indian generic drug makers to expand access to COVID-19 therapry
_3xOCqMerck said Tuesday it has entered voluntary licensing agreements with five Indian generic drug makers to expand access to molnupiravir, an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19. "The scale of human suffering in India at this moment is devastating, and it is clear that more must be done to help alleviate it," Merck Chief Executive Kenneth C. Frazier said in a statement. The agreements are with Limited, Dr. Reddy's Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited, five companies with experience as major suppliers to global procurers. Merck will also donate more than $5 million worth of oxygen-production equipment, masks, hand sanitizers and financial aid to support relief efforts in India. Shares were flat premarket and are down 5% in the year to date, while the S&P 500 has gained 11.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Apr 21, 2021
Outlook on the Inhaled Nitric Oxide Global Market to 2026 - Featuring Getinge, Merck and Halma Among Others
_3xOCqDublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications), By Region, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering. The Global Inhaled Nitric Oxide Market size is expected to reach $915.7 Million by 2026, rising at a market growth of 7% CAGR during the forecast period. Nitric oxide is a molecule of gas that causes a sense of relaxation in smooth muscle cells in the vasculature. It is because Nitric Oxide reacts with oxyhemoglobin. The gas is quickly collected by oxyhemoglobin in red blood cells and the vasodilating effects caused by inhaled nitric oxide are restricted to oxygenated areas of the lungs. Thus, this distinct ability of Nitric oxide to cause pulmonary vasodilatation in the oxygenated regions of the lung helps in enhancing oxygenation of the blood and reduces intrapulmonary right to left shunting. Hence, the inhaled nitric oxide is utilized to cure various cardiopulmonary conditions, like pulmonary hypertension in adults and children. Although, the usage of inhaled nitric oxide is restricted due to logistical and financial reasons.The rising prevalence of diseases in infants like a neonatal hypoxic respiratory failure (HRF) and persistent pulmonary hypertension is among the key driving factors of the market. Moreover, the growing number of patients with chronic obstructive pulmonary disease (COPD), and acute respiratory distress syndrome (ARDS) also propel the market growth. Apart from this, the huge cost involved in the treatment & the stringent government policies on different applications of the gas are restricting the growth of Inhaled Nitric Oxide market. However, the constant R&D activities for discovering various new applications in the healthcare sector are estimated to offer profitable opportunities for expanding the global inhaled nitric oxide market during the forecast period.The declaration of WHO about the Covid-19 outbreak as a public health emergency has affected every country around the globe. During the pandemic, nitric oxide got under several experiments to test whether it can help in treating Covid-19 affected people, due to its antiviral properties and enhanced oxygenation. Inhaled Nitric Oxide is useful in safeguarding the frontline healthcare workers from this pandemic.Application OutlookBased on Application, the market is segmented into Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease (COPD), Acute Respiratory Distress Syndrome (ARDS) and Other Applications. Neonatal respiratory treatment segment procured the substantial revenue share and is estimated to exhibit high growth rate during the forecast period. This is due a surge in the occurrences of diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF). The chronic obstructive pulmonary disease segment is expected to display promising growth rate during the forecast period.Regional OutlookBased on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the global inhaled nitric oxide market in 2019. The high growth of the regional market is due to the large consumer base & rising funding in R&D by the leading players. Major determinants such as surge in rates of chronic diseases in the newborn like persistent pulmonary hypertension, and neonatal hypoxic respiratory failure (HRF) are expected to support the market growth.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Getinge AB, Merck Group, Halma PLC, Linde PLC (Praxair, Inc.), Air Liquide S.A., Beyond Air, Inc., Mallinckrodt PLC (International Minerals and Chemical Corporation), VERO Biotech LLC, Nu-Med Plus, Inc. and Novoteris, LLC.Unique Offerings from the Publisher
Apr 19, 2021
Merck builds in Rahway ahead of global headquarters relocation
In a return to its roots, Merck will be moving its global headquarters back to the city, and that's welcome news to Mayor Raymond Giacobbe. Giacobbe announced the news as part of his virtual 2021 State of the City address last week. Merck plans to relocate its headquarters from Kenilworth to Rahway last year.
Apr 15, 2021
Merck stops developing drug intended for hospitalized COVID-19 patients
Drugmaker Merck said Thursday it was ending plans to continue to study the experimental coronavirus drug molnupiravir in hospitalized coronavirus patients, but will continue to a Phase 3 in individuals who were recently infected.
Apr 15, 2021
MERCK INVESTS €20 MILLION TO EXPAND MANUFACTURING CAPABILITIES IN JAPAN
EMD Electronics, a business of Merck KGaA (Darmstadt, Germany) announced an investment of €20 million to expand research and development and manufacturing capabilities at its site in Shizuoka, Japan. As part of this plan, new infrastructure will be built to advance and accelerate innovations in the electronic materials space. The investment is scheduled to be completed by January 2022.

Merck Blogs

May 28, 2020
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by 40% and More Than Doubled Median Progression-Free Survival Versus Chemotherapy KEYNOTE-177 is the First Positive Head-to-Head Phase 3 Trial of a Single-Agent, Anti-PD-1 Therapy Compared to Chemotherapy as First-Line Treatment for Patients with MSI-H Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-177, a Phase 3 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the first-line treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Justine Moore (908) 740-6449 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck Announces Third-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020. Payment will be made on July 7, 2020 to shareholders of record at the close of business on June 15, 2020. About Merck Language: English Contact: Media: Pamela Eisele (267) 305-3558 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck to Acquire Themis
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. Language: English Contact: Merck Media: Patrick Ryan +1 (201) 452-2409 Ian McConnell +1 (973) 901-5722 Themis Media & Investors Gretchen Schweitzer +49 172 861 8540 Jacob Verghese +49 89 2388 7731 Merck Investors: Peter Dannenbaum +1 (908) 740-1037 Michael DeCarbo +1 (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 20, 2020
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA or ATM Mutations, A Key Secondary Endpoint in the Phase 3 PROfound Trial Approximately 20-30% of Men with Metastatic Castration-Resistant Prostate Cancer Have an HRR Gene Mutation KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Patients will be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Steve Wanczyk (267) 305-5563 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE Organization,Facebook,Merck @Merck read more
May 19, 2020
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Dateline City: KENILWORTH, N.J. & PITTSBURGH Agreement Includes Strategic Investments from UPMC Enterprises and Merck Global Health Innovation Fund KENILWORTH, N.J. & PITTSBURGH--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease management, clinical decision-support and precision antibiotic therapy. Language: English Contact: UPMC Contact: Courtney Caprara Office: 412-647-6190 Mobile: 412-592-8134 E-mail: CapraraCL@upmc.edu UPMC Contact: Wendy Zellner Office: 412-586-9777 Mobile: 412-973-7266 Email: ZellnerWL@upmc.edu Merck Media Contact: Pamela Eisele 267-305-3558 Merck Investor Relations Contact: Peter Dannenbaum 908-740-1037 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 18, 2020
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Matthew Walsh and Rachel Stahler as Chief Financial Officer and Chief Information Officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses. Language: English Contact: Media: Jessica Fine (908) 740-1707 Kate Vossen (732) 675-8448 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

You may also be interested in Related companies

logo
NED Biosystems
HQ
Cambridge, US
Employees
8 
NED Biosystems is a clinical-stage company developing cancer treatments as well as HIV/AIDS and diabetes treatments.
View company
logo
SynDevRx
HQ
Cambridge, US
Employees
8 
SynDevRx is a company dedicated to developing treatments for patients whose cancer is associated with metabolic dysfunction.
View company
logo
Alteogen
Alteogen is a biopharmaceutical company that develops therapeutic proteins, antibody-drug conjugates, (ADC), and monoclonal antibody biosimilars.
View company
logo
Applied Therapeutics
HQ
New York, US
Employees
11  10increase
Applied Therapeutics is a clinical-stage biopharmaceutical company developing therapies for diabetic complications.
View company
When was Merck founded?
Merck was founded in 1891.
Who are Merck key executives?
Merck's key executives are Kenneth Frazier, Sanat Chattopadhyay and Steven C. Mizell.
How many employees does Merck have?
Merck has 71,000 employees.
What is Merck revenue?
Latest Merck annual revenue is $47.99 b.
What is Merck revenue per employee?
Latest Merck revenue per employee is $659.72 k.
Who are Merck competitors?
Competitors of Merck include Bausch Health, Sanofi and Zoetis.
Where is Merck headquarters?
Merck headquarters is located at 2000 Galloping Hill Rd, Kenilworth.
Where are Merck offices?
Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and 254 other locations
How many offices does Merck have?
Merck has 266 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu